SSG
EWTX icon

Summit Securities Group’s Edgewise Therapeutics EWTX Stock Holding History

Summit Securities Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-678
Closed -$21.4K – 1224
2026
Q1 		$21.4K Buy
+678
New +$19.6K ﹤0.01% 509
2025
Q2 		– Sell
-198
Closed -$4.36K – 1180
2025
Q1 		$4.36K Buy
+198
New +$5.19K ﹤0.01% 617

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Summit Securities Group's EWTX Position: Q2 2026 in Review

Summit Securities Group sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 678 shares — an estimated $21.4K sold.

Summit Securities Group first reported a position in EWTX in Q1 2025 and held it in 2 quarters. The position peaked at $21.4K in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Summit Securities Group reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 678 Edgewise Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Summit Securities Group first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 2 quarters.
  • Summit Securities Group's Edgewise Therapeutics position peaked at $21.4K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.